Renovaro Launches Augusta, an AI-Powered Precision Neurology Platform
Renovaro (NASDAQ: RENB) has launched Augusta, an AI-powered Precision Neurology Platform designed to accelerate drug discovery and improve treatment outcomes for neurological disorders. The platform integrates with Renovaro's existing Cube and Elion platforms and has been validated through work in Parkinson's Disease and epilepsy.
Augusta's key features include advanced data preprocessing, phenoclustering for patient subgroup identification, biomarker discovery through multimodal data analysis, in silico screening using generative frameworks, and closed-loop validation using CRISPR-modified zebrafish. The platform has already demonstrated success by identifying novel patient subgroups in Parkinson's Disease and developing lead compounds for specific epilepsy populations with rare genetic mutations.
Renovaro is currently pursuing strategic partnerships with academic medical centers and life sciences companies to expand its precision neurology efforts into additional neurological disorders.
Renovaro (NASDAQ: RENB) ha lanciato Augusta, una piattaforma di Neurologia di Precisione potenziata dall'IA, progettata per accelerare la scoperta di farmaci e migliorare i risultati terapeutici nelle patologie neurologiche. La piattaforma si integra con le piattaforme Cube ed Elion di Renovaro ed è stata validata attraverso studi su Morbo di Parkinson ed epilessia.
Le principali caratteristiche di Augusta includono un avanzato preprocessing dei dati, il fenocluster per l'identificazione di sottogruppi di pazienti, la scoperta di biomarcatori tramite analisi multimodale dei dati, screening in silico mediante framework generativi e validazione a ciclo chiuso utilizzando zebrafish modificati con CRISPR. La piattaforma ha già dimostrato successo identificando nuovi sottogruppi di pazienti nel Morbo di Parkinson e sviluppando composti leader per popolazioni epilettiche specifiche con rare mutazioni genetiche.
Renovaro sta attualmente cercando partnership strategiche con centri medici accademici e aziende delle scienze della vita per espandere le sue attività di neurologia di precisione ad altri disturbi neurologici.
Renovaro (NASDAQ: RENB) ha lanzado Augusta, una plataforma de Neurología de Precisión impulsada por IA, diseñada para acelerar el descubrimiento de fármacos y mejorar los resultados del tratamiento en trastornos neurológicos. La plataforma se integra con las plataformas Cube y Elion de Renovaro y ha sido validada mediante trabajos en Enfermedad de Parkinson y epilepsia.
Las características clave de Augusta incluyen un procesamiento avanzado de datos, fenocluster para la identificación de subgrupos de pacientes, descubrimiento de biomarcadores a través del análisis multimodal de datos, cribado in silico usando marcos generativos y validación en circuito cerrado utilizando peces cebra modificados con CRISPR. La plataforma ya ha demostrado éxito al identificar nuevos subgrupos de pacientes con Enfermedad de Parkinson y desarrollar compuestos líderes para poblaciones específicas de epilepsia con mutaciones genéticas raras.
Renovaro está actualmente buscando alianzas estratégicas con centros médicos académicos y empresas de ciencias de la vida para ampliar sus esfuerzos en neurología de precisión a otros trastornos neurológicos.
Renovaro (NASDAQ: RENB)는 신경학적 장애 치료 결과 개선과 신약 개발 가속화를 위해 AI 기반 정밀 신경학 플랫폼인 Augusta를 출시했습니다. 이 플랫폼은 Renovaro의 기존 Cube 및 Elion 플랫폼과 통합되었으며 파킨슨병과 간질 연구를 통해 검증되었습니다.
Augusta의 주요 기능으로는 고급 데이터 전처리, 환자 하위 그룹 식별을 위한 표현형 클러스터링, 다중 모달 데이터 분석을 통한 바이오마커 발견, 생성적 프레임워크를 활용한 인실리코 스크리닝, CRISPR로 수정된 제브라피시를 이용한 폐쇄 루프 검증이 포함됩니다. 이 플랫폼은 이미 파킨슨병 환자의 새로운 하위 그룹을 식별하고 희귀 유전 변이를 가진 특정 간질 환자군을 위한 선도 화합물을 개발하는 데 성공을 거두었습니다.
Renovaro는 현재 정밀 신경학 분야를 다른 신경계 질환으로 확장하기 위해 학술 의료 센터 및 생명과학 기업과의 전략적 파트너십을 모색하고 있습니다.
Renovaro (NASDAQ : RENB) a lancé Augusta, une plateforme de neurologie de précision alimentée par l'IA, conçue pour accélérer la découverte de médicaments et améliorer les résultats des traitements des troubles neurologiques. La plateforme s'intègre aux plateformes Cube et Elion existantes de Renovaro et a été validée grâce à des travaux sur la maladie de Parkinson et l'épilepsie.
Les principales fonctionnalités d'Augusta comprennent un prétraitement avancé des données, le phénoclustering pour l'identification de sous-groupes de patients, la découverte de biomarqueurs via l'analyse multimodale des données, le criblage in silico utilisant des cadres génératifs, et la validation en boucle fermée avec des poissons-zèbres modifiés par CRISPR. La plateforme a déjà démontré son efficacité en identifiant de nouveaux sous-groupes de patients atteints de la maladie de Parkinson et en développant des composés leaders pour des populations spécifiques d'épilepsie avec des mutations génétiques rares.
Renovaro recherche actuellement des partenariats stratégiques avec des centres médicaux universitaires et des entreprises des sciences de la vie afin d'étendre ses efforts en neurologie de précision à d'autres troubles neurologiques.
Renovaro (NASDAQ: RENB) hat Augusta vorgestellt, eine KI-gestützte Precision Neurology Plattform, die darauf ausgelegt ist, die Wirkstoffentdeckung zu beschleunigen und Behandlungsergebnisse bei neurologischen Erkrankungen zu verbessern. Die Plattform integriert sich in Renovaros bestehende Cube- und Elion-Plattformen und wurde durch Arbeiten an Morbus Parkinson und Epilepsie validiert.
Zu den Hauptmerkmalen von Augusta gehören fortgeschrittene Datenvorverarbeitung, Phenocluster zur Identifikation von Patientensubgruppen, Biomarkerentdeckung durch multimodale Datenanalyse, In-silico-Screening mittels generativer Frameworks sowie geschlossene Validierung mit CRISPR-modifizierten Zebrafischen. Die Plattform hat bereits Erfolge gezeigt, indem sie neuartige Patientensubgruppen bei Morbus Parkinson identifizierte und Leitverbindungen für spezifische Epilepsie-Populationen mit seltenen genetischen Mutationen entwickelte.
Renovaro strebt derzeit strategische Partnerschaften mit akademischen medizinischen Zentren und Unternehmen der Lebenswissenschaften an, um seine Precision Neurology Aktivitäten auf weitere neurologische Erkrankungen auszuweiten.
- Successfully validated platform through work in Parkinson's Disease and epilepsy
- Platform reduces experimental time and number of animal tests needed through in silico screening
- Identified novel patient subgroups and biomarkers in Parkinson's Disease
- Developed new lead compounds for specific epilepsy populations
- Potential for expansion into additional neurological disorders through strategic partnerships
- None.
Insights
Renovaro's Augusta platform signals a leap in neurological drug discovery, combining AI/ML with biological validation to potentially accelerate treatments for difficult disorders.
Renovaro's launch of Augusta represents a significant advancement in precision neurology, addressing a critical gap in healthcare where diagnosis and treatment have historically lagged. The platform's architecture demonstrates sophisticated integration of AI technology with biological validation – a combination often missing in many biotech AI announcements.
What makes Augusta particularly noteworthy is its comprehensive approach to the full drug discovery pipeline. The platform begins with data preprocessing using a patented method that optimizes decision points, followed by phenoclustering to identify meaningful patient subgroups. This is crucial in neurology where patient heterogeneity has been a major obstacle to effective treatments.
The biomarker identification capabilities leverage both clinical and molecular features through transformer models, while the in silico screening component could substantially reduce experimental resource requirements. Most importantly, Augusta includes closed-loop validation using CRISPR-modified zebrafish models with computer vision technology – providing rapid feedback on both efficacy and toxicity.
Early validation in Parkinson's Disease and epilepsy demonstrates practical application rather than theoretical potential. For epilepsy specifically, the company claims to have identified novel compounds for patients with rare genetic mutations – a potentially significant advancement for underserved patient populations.
The platform's emphasis on interpretability addresses a common criticism of AI in healthcare. By avoiding black-box approaches, Augusta may find faster regulatory and clinical acceptance. The modular infrastructure also allows for continuous improvement without disrupting established workflows.
However, investors should note that while the platform shows promise, Renovaro is still seeking strategic partnerships, indicating that commercial implementation may be in early stages. The real test will be whether Augusta can deliver measurable advantages in development timelines and success rates compared to traditional approaches.
New Proprietary Target Discovery and Validation Platform Integrates Multiomics, Contingent AI, Phenoclustering, and CRISPR Screens to Accelerate Drug Discovery
LOS ANGELES, May 14, 2025 (GLOBE NEWSWIRE) -- Renovaro Inc. (NASDAQ: RENB), an AI-driven precision medicine company that leverages AI/ML platforms to improve outcomes for cancer and neurologically challenged patients, today announced it has launched Augusta, a Precision Neurology Platform for patient stratification, biomarker discovery, drug discovery, and validation. Augusta is focused on neurology where diagnosis and treatment have historically lagged. Built on the company’s Renovaro Cube and Elion platforms and recently validated through work in Parkinson’s Disease and epilepsy, the platform combines multimodal data analytics with proprietary in silico screening to identify biomarkers and therapeutics in a fraction of the time of conventional methods.
Neurological disorders remain among the most difficult to diagnose and treat due to heterogeneity in symptoms, unclear disease boundaries, and limited biomarkers. Augusta addresses these challenges through:
- Data Preprocessing: Augusta is the first biomedical-specific machine learning (ML) platform to perform fast, effective data pre-processing. It uses a patented process to enable optimization of all decision points in data processing, reducing bias and improving results for drug discovery/development, diagnostics, and precision medicine.
- Phenoclustering: Advanced clustering of patient-level phenotypic and clinical data to define biologically and clinically meaningful subgroups.
- Biomarker identification: Fusion of multimodal data pipelines with predictive analytics to derive precise, actionable biomarkers. Biomarkers include clinical features, as well as molecular features identified using proprietary transformer models designed to detect mutations and epigenetic alterations.
- In silico screening: Proprietary models built on generative frameworks that predict the effect of disrupting thousands of genes in silico, reducing the number of experiments and animals used.
- Closed loop validation: Initial validation in CRISPR modified zebrafish empowered by proprietary computer vision models provides fast confirmation of gene and small molecule effects on brain development and behaviour, while simultaneously providing readouts on unwanted toxicities in specific genetic backgrounds.
Unlike black-box approaches, the Augusta platform emphasizes interpretability, clinical alignment, and rigorous benchmarking. Augusta’s modular infrastructure enables plug-and-play model evaluation, including for large language models (LLMs) conditioned using proprietary knowledge graphs. This supports continuous innovation while maintaining clinical and experimental robustness.
“The Augusta platform is about validation,” said David Weinstein, Renovaro CEO. “We’re setting a new bar for how AI can be responsibly and effectively deployed in clinical and experimental settings.”
The efficacy of this approach has already been demonstrated in Parkinson’s Disease, where phenoclustering identified novel and highly predictable patient subgroups with unique clinical characteristics and biomarkers, and in epilepsy, where novel lead compounds were identified specifically addressing patient populations with rare genetic mutations.
With a strong foundation in Parkinson’s disease and epilepsy, Renovaro plans to expand its precision neurology efforts into additional neurological disorders. Strategic partnerships with academic medical centres and life sciences companies are currently being discussed.
About Renovaro
Renovaro https://renovarogroup.com/ aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube that is leveraging AI for multi-omic diagnostics and drug development, and BioSymetrics which specializes in contingent AI for precision neurology. For more information, visit www.renovarogroup.com.
Forward-Looking Statements
This press release contains statements by Renovaro Biosciences Inc. (“Renovaro”, “we”, “us”, “our” or the “Company”) that are not historical facts and are considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may address, among other things, our prospects, plans, business strategy and expected financial and operational results. You can identify these statements by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will,” “would”, ”could”, ”project”, ”plan”, “potential”, ”designed”, “seek”, “target”, variations of these terms, the negatives of such terms and similar expressions. These statements are based on certain assumptions that we have made in light of our experience in our industry as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate in these circumstances. These forward-looking statements are based on our current expectations and beliefs concerning future developments and their potential effect on us. You should not rely on forward-looking statements because our actual results may differ materially from those indicated by forward-looking statements as a result of a number of important factors. These factors include, but are not limited to: the success or efficacy of our pipeline, platform and fundraising; our ability to successfully integrate business that we have acquired, including BioSymetrics, or that we may acquire; our ability to achieve the benefits that we expect to realize as a result of our acquisitions, including BioSymetrics; and those other risks and uncertainties discussed in the reports we have filed with the Securities and Exchange Commission (the “SEC”), such as our most recent Annual Report on Form 10-K and our subsequently filed Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. All forward-looking statements are qualified in their entirety by this cautionary statement. Forward-looking statements speak only as of the date the statements were made. We do not undertake any obligation to update forward-looking information, except to the extent required by applicable law.
Investor Relations
Chris Tyson
Executive Vice President
MZ Group - MZ North America
949-491-8235
RENB@mzgroup.us
www.mzgroup.us
For media inquiries, please contact:
FAQ
What is Renovaro's (RENB) Augusta platform and what does it do?
How has Renovaro's Augusta platform been validated so far?
What are the key features of Renovaro's (RENB) Augusta platform?
What are Renovaro's future plans for the Augusta platform?
How does Augusta's technology reduce the need for animal testing?
